Journal of Clinical Oncology
Articles in this Issue
Impact of diagnostic workup location on time to treatment for patients with non-small cell lung cancer seen in the emergency department.
e13518 Background: Most non-small cell lung cancer (NSCLC) diagnoses begin in the emergency department (ED), despite ED diagnoses being associated with hi...
Assessing oncology fellows' insights to enhance cancer care: A quality improvement initiative.
e23241 Background: Improving cancer care requires integrating feedback from oncology fellows actively involved in patient management. Our program, consist...
Phase 1 first-in-human clinical trial of AG01, a recombinant monoclonal antibody to progranulin/glycoprotein 88 (PGRN/GP88), to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor response in subjects with advanced solid tumor malignancies.
TPS3180 Background: GP88/PGRN is the largest member of the granulin/epithelin family. We demonstrated GP88’s role as an autocrine growth & survival fa...
Oncologists' attitudes and beliefs toward crying with patients and its correlation with burnout.
9013 Background: This pilot study examines oncologists' perspectives on expressing emotion, particularly crying, in the presence of patients, the frequenc...
A phase II clinical study of neoadjuvant penpulimab combined with chemotherapy for patients with locoregionally advanced, resectable squamous cell carcinoma of the head and neck.
e18098 Background: Locally advanced squamous cell carcinoma of the head and neck (HNSCC) is associated with high risks of local recurrence and distant met...
Comparison of survival outcomes of transoral surgery with or without adjuvant chemoradiotherapy vs chemoradiotherapy alone for oropharyngeal cancer: A systematic review and meta-analysis.
e18109 Background: Oropharyngeal cancer is a type of head and neck cancer that starts in the tissues of the oropharynx. Optimal treatment strategies for o...
Dual targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma.
TPS2101 Background: Patients with recurrent glioblastoma have limited effective treatment options due to the highly immunosuppressive microenvironment and...
Incidence and outcomes of rejection in solid organ transplant recipients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
11068 Background: Immune checkpoint inhibitors (ICIs) are a cornerstone in the treatment of many solid tumors; however, their use in cancer patients with...
From liver to life: The overlooked impact of MASLD on digestive cancer outcomes.
e23070 Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is an increasing public health concern with the potential to increase...
Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
4567 Background: Effective and tolerable therapies for patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in the first-line set...
Homologous recombination deficiency (HRD) profiling in Chinese pancreatic ductal adenocarcinoma: Implications for platinum-based chemotherapy.
4165 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis. While platinum-based therapies have demonstrat...
A phase II study of an anti-telomerase CD4+ T-helper vaccine (UCPVax) with or without temozolomide in newly diagnosed glioblastoma.
2006 Background: UCPVax is a therapeutic vaccine designed to stimulate CD4+ helper T cell responses against telomerase (TERT), a protein highly expressed...
Mevrometostat in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 study.
TPS5116 Background: Mevrometostat is a potent, selective inhibitor of the histone methyltransferase enhancer of zeste 2 (EZH2), which is canonically invol...
Efficacy of treatment with traditional Chinese medicine (Renshen Yangrong Tang granules) for cancer-related fatigue in patients with platinum-based chemotherapy: A randomized, double- blinded, placebo-controlled, multicenter trial.
12012 Background: Although there is higher incidence of cancer-related fatigue (CRF) in patients undergoing chemotherapy, effective drugs is still in need...
Dinutuximab beta for the treatment of Ewing sarcoma.
e23503 Background: Ewing sarcoma is a rare and aggressive cancer with poor prognosis particularly for metastatic or recurrent cases. As GD2 is expressed o...
Colonoscopy quality indicators for colorectal cancer precursors: Sessile serrated lesion and adenoma detection rates from a large clinical study of a blood-based test for CRC screening.
10525 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. Colonoscopy can reduce mortality by removing prec...
Clinical analysis of AFFINITY trial: Quantification of tumor-specific antibodies and immune cell activation following Aliya PEF ablation in stage IV cancer patients.
e20503 Background: Tumor ablation is generally restricted to control focal disease. There have been rare reports of off-target tumor response (abscopal ef...
Differences in peripheral blood immune cells composition and pathway expression between non-Hispanic Black and non-Hispanic White females at different disease states of breast cancer.
e12564 Background: Racial differences in breast cancer are well established. Compared to non-Hispanic white (NHW) women, non-Hispanic Black (NHB) women ha...
TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.
TPS8668 Background: Eftilagimod alfa (E), an antigen presenting cell activator, binds to a subset of MHC class II molecules to mediate T cell (CD4/CD8) re...
Intensification of androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): Patterns of use and impact on outcomes from a large academic medical center.
e17115 Background: ADT intensification with docetaxel and/or androgen receptor pathway inhibitors (ARPIs) has survival benefit in mHSPC. While triplet (AD...
Exploring racial disparities in oropharyngeal squamous cell carcinoma.
e13813 Background: Oropharyngeal squamous cell carcinoma (OPSCC) demonstrates distinct survival outcomes based on its etiology: p16+ disease associated wi...
AXALAP: Phase Ib study of axatilimab in combination with olaparib in <i>BRCA1/2</i> and <i>PALB2</i> -associated metastatic HER2-negative breast cancer (BC).
TPS1143 Background: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have revolutionized the treatment of patients (pts) with germline BR...
Late toxicities (LT) in patients affected by locally advanced (LA) oropharyngeal carcinoma (OPC) treated with definitive (chemo)radiotherapy (C)RT: Risk factors and pattern of adverse effects.
e18111 Background: Treatment with CRT has a high burden of acute toxicities in OPCs patients, but data regarding LT are scarce. The more favourable progno...
Impact of frailty on outcomes in elderly pancreatic cancer patients undergoing chemotherapy: A National Inpatient Sample analysis.
e16398 Background: The healthcare burden of pancreatic cancer in the United States is exponentially growing, with an added impact on the elderly populatio...
Tackling the high economic impact of recurrence in resected Medicare patients with early-stage triple-negative breast cancer.
e13581 Background: Patients with resected triple negative breast cancer who experience recurrence have poorer survival outcomes, but the economic impact o...